7cebd572-2edd-4351-b59e-fb4417a46b9c
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.400
- ESTROGEN_RESPONSE_LATE+0.400
- INTERFERON_ALPHA_RESPONSE+0.400
- INTERFERON_GAMMA_RESPONSE+0.400
- KRAS_SIGNALING_DN+0.400
- COAGULATION+0.300
- IL6_JAK_STAT3_SIGNALING+0.300
- INFLAMMATORY_RESPONSE+0.300
- APICAL_JUNCTION+0.200
- APICAL_SURFACE+0.200
Top 10 suppressed
- MYC_TARGETS_V1-0.600
- PROTEIN_SECRETION-0.600
- UNFOLDED_PROTEIN_RESPONSE-0.600
- E2F_TARGETS-0.500
- G2M_CHECKPOINT-0.500
- MITOTIC_SPINDLE-0.500
- MTORC1_SIGNALING-0.500
- ANDROGEN_RESPONSE-0.400
- DNA_REPAIR-0.400
- MYC_TARGETS_V2-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD001535_R2.RNA-Seq | EPN | Posterior Fossa EPN | 0.940 |
| 2 | SRR1468141 | GTEX | — | 0.931 |
| 3 | BS_GTZCFGRZ | Ganglioglioma | — | 0.930 |
| 4 | SRR1358826 | GTEX | — | 0.928 |
| 5 | SJEPD001523_R1.RNA-Seq | EPN | Posterior Fossa EPN | 0.922 |
| 6 | SRR598894 | GTEX | — | 0.922 |
| 7 | SRR1391598 | GTEX | — | 0.920 |
| 8 | SRR8392886 | — | cohortA1 | 0.920 |
| 9 | BS_2SHWPB5P | ganglioneuroblastoma | — | 0.919 |
| 10 | 2d8d97e6-b599-4444-8e11-73adb55be0be | — | — | 0.918 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.400 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.400 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.400 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.400 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.400 | Remibrutinib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.300 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.200 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| COMPLEMENT | 0.200 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.200 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.200 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.200 | Inavolisib | — uncovered |
| MYOGENESIS | 0.200 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.200 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.100 | Remibrutinib | — uncovered |
| HYPOXIA | 0.100 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.100 | Idelalisib | — uncovered |